Fool.com
The World's Greatest Investing Community
Results 71 - 80 of 428 : Previous 4 5 6 7 8 9 10 11 12 Next
Glaxo Goes Head-to-Head on HPV
The drug company takes a chance on a risky trial.
Investing Against Breast Cancer
Many companies are interested in both a cure and a large lucrative market.
Derailed and Built to Stay That Way
Investors aren't happy with Biovail's plan to get back on track.
Beware: Some dividends might look alike, but they can be very different.
Insider trading needs to be stopped.
Parachutes, Cliffs, and Softer Landings
Bristol-Myers gets ready to fly -- or fall.
The Other 33.1% of Pfizer Reports
Wyeth reports earnings, but investors need only look at the top line.
Slimming down in anticipation of L-day.
Foolish Forecast: Pfizer's Out of the Starting Gate
Clues you can use for tomorrow's news.
Johnson & Johnson's Simponi Sticks to the Wall
Johnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA.
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK